Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Crit Rev Toxicol ; 54(6): 418-429, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38869005

RESUMEN

In the risk assessment of agrochemicals, there has been a historical paucity of using data to refine the default adjustment factors, even though large datasets are available to support this. The current state of the science for addressing uncertainty regarding animal to human extrapolation (AFA) is to develop a "data-derived" adjustment factor (DDEF) to quantify such differences, if data are available. Toxicokinetic (TK) and toxicodynamic (TD) differences between species can be utilized for the DDEF, with human datasets being ideal yet rare. We identified a case for a currently registered herbicide, mesotrione, in which human TK and TD are available. This case study outlines an approach for the development of DDEFs using comparative human and animal data and based on an adverse outcome pathway (AOP) for inhibition of 4-hydroxyphenol pyruvate dioxygenase (HHPD). The calculated DDEF for rat to human extrapolation (AFA) for kinetics (AFAK = 2.5) was multiplied by the AFA for dynamics (AFAD = 0.3) resulting in a composite DDEF of ∼1 (AFA = 0.75). This reflects the AOP and available scientific evidence that humans are less sensitive than rats to the effects of HPPD inhibitors. Further analyses were conducted utilizing in vitro datasets from hepatocytes and liver cytosols and extrapolated to whole animal using in vitro to in vivo extrapolation (IVIVE) to support toxicodynamic extrapolation. The in vitro datasets resulted in the same AFAD as derived for in vivo data (AFAD = 0.3). These analyses demonstrate that a majority of the species differences are related to toxicodynamics. Future work with additional in vitro/in vivo datasets for other HPPD inhibitors and cell types will further support this result. This work demonstrates utilization of all available toxicokinetic and toxicodynamic data to replace default uncertainty factors for agrochemical human health risk assessment.


Asunto(s)
4-Hidroxifenilpiruvato Dioxigenasa , Ciclohexanonas , Humanos , Animales , Ratas , Ciclohexanonas/toxicidad , Medición de Riesgo , 4-Hidroxifenilpiruvato Dioxigenasa/antagonistas & inhibidores , Especificidad de la Especie , Herbicidas/toxicidad , Toxicocinética , Rutas de Resultados Adversos
2.
J Appl Toxicol ; 43(1): 186-194, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36017531

RESUMEN

Uncertainty factors (UFs) are used to account for uncertainties and variability when setting exposure limits or guidance values. Starting from a proposal of a single UF of 100 to extrapolate from an animal NOAEL to a human acceptable exposure, the aspects of uncertainty and number of UFs have diversified and today there are several risk assessment guidelines that contain schemes of default UFs of varying complexity. In the present work, we scoped the scientific literature on default UFs to map developments regarding recommendations and evaluations of these. We identified 91 publications making recommendations for one or several UFs and 55 publications evaluating UFs without making explicit recommendations about numerical values; these were published between 1954 and 2021. The 2000s was the decade with the largest number of publications, interspecies differences and intraspecies variability being the most frequent topics. The academic sector has been the most active (76 out of 146 publications). Authors from the private sector more often presented UF recommendations, but differences between sectors regarding size of recommendations were not statistically significant. The empirical underpinning of the reviewed recommendations ranges from four to 462 chemicals, that is, relatively low numbers compared with the range of chemicals these default UFs are expected to cover. The recommended UFs have remained remarkably constant, with merely a slight decrease over time. Although chemical specific UFs are preferable, the widespread use of default UFs warrants further attention regarding their empirical and normative basis.


Asunto(s)
Salud , Incertidumbre , Animales , Humanos , Nivel sin Efectos Adversos Observados , Medición de Riesgo , Estado de Salud
3.
Environ Sci Technol ; 56(12): 8552-8560, 2022 06 21.
Artículo en Inglés | MEDLINE | ID: mdl-35657801

RESUMEN

Today's scarcity of animal toxicological data for nanomaterials could be lifted by substituting in vivo data with in vitro data to calculate nanomaterials' effect factors (EF) for Life Cycle Assessment (LCA). Here, we present a step-by-step procedure to calculate in vitro-to-in vivo extrapolation factors to estimate human Benchmark Doses and subsequently in vitro-based EFs for several inhaled nonsoluble nanomaterials. Based on mouse data, the in vitro-based EF of TiO2 is between 2.76 · 10-4 and 1.10 · 10-3 cases/(m2/g·kg intake), depending on the aerodynamic size of the particle, which is in good agreement with in vivo-based EFs (1.51 · 10-4-5.6 · 10-2 cases/(m2/g·kg intake)). The EF for amorphous silica is in a similar range as for TiO2, but the result is less robust due to only few in vivo data available. The results based on rat data are very different, confirming the importance of selecting animal species representative of human responses. The discrepancy between in vivo and in vitro animal data in terms of availability and quality limits the coverage of further nanomaterials. Systematic testing on human and animal cells is needed to reduce the variability in toxicological response determined by the differences in experimental conditions, thus helping improve the predictivity of in vitro-to-in vivo extrapolation factors.


Asunto(s)
Nanoestructuras , Dióxido de Silicio , Animales , Humanos , Estadios del Ciclo de Vida , Ratones , Tamaño de la Partícula , Ratas , Solubilidad , Titanio/toxicidad
4.
AAPS J ; 23(1): 24, 2021 01 12.
Artículo en Inglés | MEDLINE | ID: mdl-33438174

RESUMEN

Oxycodone is an opioid analgesic that is commonly prescribed to pregnant women to treat moderate-to-severe pain. It has been shown to cross the placenta and distribute to the fetus. Oxycodone is mainly metabolized by CYP3A4 in the adult liver. Since CYP3A7 is abundantly expressed in the fetal liver and has overlapping substrate specificity with CYP3A4, we hypothesized that the fetal liver may significantly limit fetal exposure to oxycodone. This study showed that oxycodone is metabolized by CYP3A7 to noroxycodone in fetal liver microsomes (FLMs). The measured CYP3A7 expression was 191-409 pmol/mg protein in 14 FLMs, and an intersystem extrapolation factor (ISEF) for CYP3A7 was 0.016-0.066 in the panel of fetal livers using 6ß-OH-testosterone formation as the probe reaction. Noroxycodone formation in the fetal liver was predicted from formation rate by recombinant CYP3A7, CYP3A7 expression level and the established ISEF value with average fold error of 1.25. Based on the intrinsic clearance of oxycodone measured in FLM, the fetal hepatic clearance (CLh) at term was predicted to be 495 (range: 66.4-936) µL/min, a value that is > 99% lower than the predicted adult liver CLh. The predicted fetal hepatic extraction ratio was 0.0019 (range: 0.00003-0.0036). These results suggest that fetal liver metabolism does not quantitatively contribute to the total systemic clearance of oxycodone in pregnant women nor does it provide a barrier for limiting fetal exposure to oxycodone. Additionally, since CYP3A7 forms noroxycodone, an inactive metabolite, the metabolism in the fetal liver is unlikely to affect fetal opioid activity.


Asunto(s)
Citocromo P-450 CYP3A/metabolismo , Feto/enzimología , Hígado/enzimología , Oxicodona/farmacocinética , Adulto , Pruebas de Enzimas , Femenino , Feto/citología , Eliminación Hepatobiliar , Humanos , Hígado/citología , Masculino , Intercambio Materno-Fetal , Microsomas Hepáticos , Morfinanos/farmacocinética , Oxicodona/administración & dosificación , Placenta , Embarazo , Cultivo Primario de Células , Proteínas Recombinantes/metabolismo
5.
Int J Hyg Environ Health ; 232: 113668, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33333487

RESUMEN

Irritation of the eyes and the upper respiratory tract are important endpoints for setting guide values for chemicals. To optimize the use of the often-limited data, we analysed controlled human exposure studies (CHS) with 1-4 h inhalation of the test substance, repeated dose inhalation studies in rodents, and Alarie-Tests and derived extrapolation factors (EF) for exposure duration, inter- and intraspecies differences. For the endpoint irritating effects in the respiratory tract in rodents, geometric mean (GM) values of 1.9 were obtained for the EF for subacute→subchronic (n = 16), 2.1 for subchronic→chronic (n = 40), and 2.9 for subacute→chronic (n = 10) extrapolation. Based on these data we suggest an EF of 2 for subchronic→chronic and of 4 for subacute→chronic extrapolation. In CHS, exposure concentration determines the effects rather than exposure duration. Slight reversible effects during 4 h exposure indicate that an EF of 1 can be considered for assessing chronic exposures. To assess species extrapolation, 10 chemicals were identified with both, reliable rat inhalation studies and CHS. The GM of the ratio between the No Observed Adverse Effect Concentration (NOAEC) in rats and humans was 2.3 and increased to 3.6 when expanding the dataset to all available EF (n = 25). Based on these analyses, an EF of 3 is suggested to extrapolate from a NOAEC in a chronic rat study to a NOAEC in a CHS. The analysis of EFs for the extrapolation from a 50% decrease in respiratory frequency in the Alarie test in mice (RD50) to a NOAEC in a CHS resulted in a GM of 40, for both, the reliable (n = 11) and the overall dataset (n = 19). We propose to use the RD50 from the Alarie test for setting guide values and to use 40 as EF. Efs for intraspecies differences in the human population must account for susceptible persons, most importantly for persons with chemical intolerance (CI), who show subjective signs of irritation at low concentrations. The limited data available do not justify to deviate from an EF of 10 - 20 as currently used in different regulatory settings.


Asunto(s)
Sistema Respiratorio , Animales , Ratones , Ratas , Medición de Riesgo
6.
Food Chem Toxicol ; 146: 111784, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32998026

RESUMEN

It was generally accepted as a default assumption that No-Observed-Adverse-Effect Levels (NOAELs) or Lowest-Observed-Adverse-Effect Levels (LOAELs) in long-term toxicity studies are lower than in short-term ones, i.e. the toxic potency increases with prolonged exposure duration. Recent studies on pesticides and industrial chemicals reported that subacute, subchronic or chronic NOAELs/LOAELs are similar when study design factors are appropriately considered. We investigated whether these findings also apply to certain food constituents. After reviewing subchronic and chronic toxicity studies on more than 100 compounds, a total of 32 compounds could be included in the analysis. Geometric mean (GM) values of subchronic vs. chronic NOAEL or LOAEL ratios ranged from 1.0 to 2.0, with a geometric standard deviation from 2.2 to 4.2, which is consistent with data reported in the literature. While for many of the investigated compounds the ratio is around 1 - suggesting that health-based guidance values could appropriately be derived from subchronic toxicity studies - our study also identified some substances with higher ratios leading to a GM of around 2. The EFSA Scientific Committee suggested to apply an uncertainty factor of 2 to extrapolate from subchronic to chronic studies and, as a precautionary approach, we concur with this suggestion.


Asunto(s)
Aditivos Alimentarios/toxicidad , Contaminación de Alimentos , Animales , Humanos , Ratones , Nivel sin Efectos Adversos Observados , Pruebas de Toxicidad Crónica , Pruebas de Toxicidad Subcrónica
7.
Environ Sci Pollut Res Int ; 26(5): 4961-4974, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30593652

RESUMEN

The main purpose of our research was to assess the chronic exposure of red foxes to Cd, Pb and Zn. We have determined concentrations of these metals in the kidney, liver and muscle of 36 red foxes hunted between December 2002 and March 2003 in differently polluted areas in southern Poland. Tissue concentrations of Pb and Cd in the red foxes significantly co-varied with concentrations of these elements in the soil, and differed between the tissues. We compared concentrations of Pb, Cd, and Zn in red foxes with two rodent species, Apodemus flavicollis and Myodes glareolus, trapped simultaneously in the same area. Concentrations of Pb and Cd appeared significantly higher in the red foxes than in the rodents, but the slopes of the relationship between metal concentrations in tissues and in soil were similar in all species. This indicates that extrapolation from results of monitoring studies conducted on rodents to mammalian carnivores is possible but requires applying an extrapolation factor.


Asunto(s)
Cadmio/análisis , Monitoreo del Ambiente/métodos , Contaminantes Ambientales/análisis , Zorros/metabolismo , Plomo/análisis , Roedores/metabolismo , Animales , Riñón/química , Hígado/química , Músculos/química , Polonia , Suelo/química , Especificidad de la Especie , Distribución Tisular
8.
Ann ICRP ; 47(3-4): 97-112, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29652168

RESUMEN

For stochastic effects such as cancer, linear-quadratic models of dose are often used to extrapolate from the experience of the Japanese atomic bomb survivors to estimate risks from low doses and low dose rates. The low dose extrapolation factor (LDEF), which consists of the ratio of the low dose slope (as derived via fitting a linear-quadratic model) to the slope of the straight line fitted to a specific dose range, is used to derive the degree of overestimation (if LDEF > 1) or underestimation (if LDEF < 1) of low dose risk by linear extrapolation from effects at higher doses. Likewise, a dose rate extrapolation factor (DREF) can be defined, consisting of the ratio of the low dose slopes at high and low dose rates. This paper reviews a variety of human and animal data for cancer and non-cancer endpoints to assess evidence for curvature in the dose response (i.e. LDEF) and modifications of the dose response by dose rate (i.e. DREF). The JANUS mouse data imply that LDEF is approximately 0.2-0.8 and DREF is approximately 1.2-2.3 for many tumours following gamma exposure, with corresponding figures of approximately 0.1-0.9 and 0.0-0.2 following neutron exposure. This paper also cursorily reviews human data which allow direct estimates of low dose and low dose rate risk.


Asunto(s)
Relación Dosis-Respuesta en la Radiación , Neoplasias Inducidas por Radiación/epidemiología , Dosis de Radiación , Animales , Humanos , Ratones , Neoplasias Inducidas por Radiación/etiología , Riesgo
9.
Drug Metab Pers Ther ; 32(4): 191-200, 2017 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-29176011

RESUMEN

BACKGROUND: For estimation of fractions metabolized (fm) by different hepatic recombinant human CYP enzymes (rhCYP), calculation of inter-system extrapolation factors (ISEFs) has been proposed. METHODS: ISEF values for CYP1A2, CYP2C19 and CYP3A4/5 were measured. A CYP2C9 ISEF was taken from a previous report. Using a set of compounds, fractions metabolized by CYP enzymes (fm,CYP) values calculated with the ISEFs based on rhCYP data were compared with those from the chemical inhibition data. Oral pharmacokinetics (PK) profiles of midazolam were simulated using the physiologically based pharmacokinetics (PBPK) model with the CYP3A ISEF. For other CYPs, the in vitro fm,CYP values were compared with the reference fm,CYP data back-calculated with, e.g. modeling of test substrates by feeding clinical PK data. RESULTS: In vitro-in vitro fm,CYP3A4 relationship between the results from rhCYP incubation and chemical inhibition was drawn as an exponential correlation with R2=0.974. A midazolam PBPK model with the CYP3A4/5 ISEFs simulated the PK profiles within twofold error compared to the clinical observations. In a limited number of cases, the in vitro methods could not show good performance in predicting fm,CYP1A2, fm,CYP2C9 and fm,CYP2C19 values as reference data. CONCLUSIONS: The rhCYP data with the measured ISEFs provided reasonable calculation of fm,CYP3A4 values, showing slight over-estimation compared to chemical inhibition.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Microsomas Hepáticos/enzimología , Modelos Estadísticos , Farmacocinética , Simulación por Computador , Citocromo P-450 CYP1A2/metabolismo , Citocromo P-450 CYP2C19/metabolismo , Citocromo P-450 CYP3A/metabolismo , Humanos , Mefenitoína/metabolismo , Midazolam/metabolismo , Fenacetina/metabolismo , Testosterona/metabolismo
10.
Radiat Environ Biophys ; 56(4): 299-328, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28939964

RESUMEN

Murine experiments were conducted at the JANUS reactor in Argonne National Laboratory from 1970 to 1992 to study the effect of acute and protracted radiation dose from gamma rays and fission neutron whole body exposure. The present study reports the reanalysis of the JANUS data on 36,718 mice, of which 16,973 mice were irradiated with neutrons, 13,638 were irradiated with gamma rays, and 6107 were controls. Mice were mostly Mus musculus, but one experiment used Peromyscus leucopus. For both types of radiation exposure, a Cox proportional hazards model was used, using age as timescale, and stratifying on sex and experiment. The optimal model was one with linear and quadratic terms in cumulative lagged dose, with adjustments to both linear and quadratic dose terms for low-dose rate irradiation (<5 mGy/h) and with adjustments to the dose for age at exposure and sex. After gamma ray exposure there is significant non-linearity (generally with upward curvature) for all tumours, lymphoreticular, respiratory, connective tissue and gastrointestinal tumours, also for all non-tumour, other non-tumour, non-malignant pulmonary and non-malignant renal diseases (p < 0.001). Associated with this the low-dose extrapolation factor, measuring the overestimation in low-dose risk resulting from linear extrapolation is significantly elevated for lymphoreticular tumours 1.16 (95% CI 1.06, 1.31), elevated also for a number of non-malignant endpoints, specifically all non-tumour diseases, 1.63 (95% CI 1.43, 2.00), non-malignant pulmonary disease, 1.70 (95% CI 1.17, 2.76) and other non-tumour diseases, 1.47 (95% CI 1.29, 1.82). However, for a rather larger group of malignant endpoints the low-dose extrapolation factor is significantly less than 1 (implying downward curvature), with central estimates generally ranging from 0.2 to 0.8, in particular for tumours of the respiratory system, vasculature, ovary, kidney/urinary bladder and testis. For neutron exposure most endpoints, malignant and non-malignant, show downward curvature in the dose response, and for most endpoints this is statistically significant (p < 0.05). Associated with this, the low-dose extrapolation factor associated with neutron exposure is generally statistically significantly less than 1 for most malignant and non-malignant endpoints, with central estimates mostly in the range 0.1-0.9. In contrast to the situation at higher dose rates, there are statistically non-significant decreases of risk per unit dose at gamma dose rates of less than or equal to 5 mGy/h for most malignant endpoints, and generally non-significant increases in risk per unit dose at gamma dose rates ≤5 mGy/h for most non-malignant endpoints. Associated with this, the dose-rate extrapolation factor, the ratio of high dose-rate to low dose-rate (≤5 mGy/h) gamma dose response slopes, for many tumour sites is in the range 1.2-2.3, albeit not statistically significantly elevated from 1, while for most non-malignant endpoints the gamma dose-rate extrapolation factor is less than 1, with most estimates in the range 0.2-0.8. After neutron exposure there are non-significant indications of lower risk per unit dose at dose rates ≤5 mGy/h compared to higher dose rates for most malignant endpoints, and for all tumours (p = 0.001), and respiratory tumours (p = 0.007) this reduction is conventionally statistically significant; for most non-malignant outcomes risks per unit dose non-significantly increase at lower dose rates. Associated with this, the neutron dose-rate extrapolation factor is less than 1 for most malignant and non-malignant endpoints, in many cases statistically significantly so, with central estimates mostly in the range 0.0-0.2.


Asunto(s)
Determinación de Punto Final , Rayos gamma/efectos adversos , Neoplasias Inducidas por Radiación/etiología , Neutrones/efectos adversos , Dosis de Radiación , Animales , Relación Dosis-Respuesta en la Radiación , Masculino , Ratones
11.
Environ Pollut ; 205: 240-9, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26093078

RESUMEN

Unionised ammonia (NH3) is highly toxic to freshwater organisms. Yet, most of the available toxicity data on NH3 were predominantly generated from temperate regions, while toxicity data on NH3 derived from tropical species were limited. To address this issue, we first conducted standard acute toxicity tests on NH3 using ten tropical freshwater species. Subsequently, we constructed a tropical species sensitivity distribution (SSD) using these newly generated toxicity data and available tropical toxicity data of NH3, which was then compared with the corresponding temperate SSD constructed from documented temperate acute toxicity data. Our results showed that tropical species were generally more sensitive to NH3 than their temperate counterparts. Based on the ratio between temperate and tropical hazardous concentration 10% values, we recommend an extrapolation factor of four to be applied when surrogate temperate toxicity data or temperate water quality guidelines of NH3 are used for protecting tropical freshwater ecosystems.


Asunto(s)
Amoníaco/toxicidad , Organismos Acuáticos/efectos de los fármacos , Contaminantes Químicos del Agua/toxicidad , Amoníaco/análisis , Organismos Acuáticos/crecimiento & desarrollo , Ecosistema , Monitoreo del Ambiente , Agua Dulce/análisis , Contaminantes Químicos del Agua/análisis , Calidad del Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA